Blueprint Medicines Cash Flow Statement

Financials in millions MAD. Fiscal year is January - December.

Millions MAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-	188.93	166.25	172.04	157.26	Upgrade
Depreciation & Amortization	-	88.29	157.49	130.94	131.33	Upgrade
Loss (Gain) From Sale of Assets	-	25.76	-14.08	-22.79	-7.6	Upgrade
Other Operating Activities	-	29.53	31.1	9.96	21.09	Upgrade
Change in Other Net Operating Assets	-	185.07	-468.26	147.06	-131.72	Upgrade
Operating Cash Flow	-	517.59	-127.5	437.23	170.37	Upgrade
Operating Cash Flow Growth	-	-	-	156.64%	-43.26%	Upgrade
Capital Expenditures	-	-90.71	-58.28	-79.06	-128.42	Upgrade
Sale of Property, Plant & Equipment	-	19.47	36.88	64.99	19.89	Upgrade
Investing Cash Flow	-	-71.24	-21.4	-14.08	-108.52	Upgrade
Long-Term Debt Issued	-	2.96	26.94	29.48	64.08	Upgrade
Long-Term Debt Repaid	-	-73.48	-65.59	-88.84	-1.27	Upgrade
Net Debt Issued (Repaid)	-	-70.52	-38.65	-59.35	62.81	Upgrade
Common Dividends Paid	-	-122.64	-113.88	-	-	Upgrade
Other Financing Activities	-	-15.82	-16.98	-20.02	-27.08	Upgrade
Financing Cash Flow	-	-208.97	-169.51	-79.37	35.73	Upgrade
Net Cash Flow	-	237.38	-318.4	343.78	97.57	Upgrade
Free Cash Flow	-	426.88	-185.78	358.16	41.95	Upgrade
Free Cash Flow Growth	-	-	-	753.79%	-74.73%	Upgrade
Free Cash Flow Margin	-	13.59%	-6.64%	14.09%	1.67%	Upgrade
Free Cash Flow Per Share	-	4.87	-2.12	4.09	0.48	Upgrade
Levered Free Cash Flow	-	333.14	-153.54	283.27	93.17	Upgrade
Unlevered Free Cash Flow	-	343.94	-140.98	297.33	114.04	Upgrade
Change in Net Working Capital	-53.33	-157.99	426.87	-90.79	53.77	Upgrade

Updated Sep 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.